NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Clinical trial NCT05704829 · RECRUITING

Trial details

NCT number: NCT05704829
Sponsor: Women's Cancer Study Group GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Early Breast Cancer

Start date: 2024-02-05
Primary completion: 2030-06-01
Enrollment: 702

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.